MYCN and neoplasm: Taschner-Mandl and collaborators [26] found that metronomic topotecan in vitro (5 nM for 3 weeks) selectively promoted DNA damage and a tumor-inhibiting favorable senescence-associated secretory phenotype (SASP) in aggressive MYCN-amplified neuroblastoma cells (i.e., STA-NB-10 and CLB-Ma).